Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

Completed · Phase 3 · Has a placebo group

Conditions studied: COVID-19

In brief

ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests, oropharyngeal (OP) swabs, plasma (Day 29), and serum for secondary research as well as clinical outcome data. However, if infection control or other restrictions limit the ability of the subject to return to the clinic, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary objective is to evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.

Key facts

Study ID

NCT04640168

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

1010

Starts

2020-12-02

Expected to finish

2021-06-18

Last updated by the study team

2022-06-28

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hospitalized with symptoms suggestive of COVID-19.
• Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures and understands and agrees to comply with planned study procedures.
• Male or non-pregnant female adult > / = 18 years of age at time of enrollment.
• Illness of any duration and has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay (e.g. NAAT, antigen test) in any respiratory specimen or saliva < / = 14 days prior to randomization.
• Within the 7 days prior to randomization requiring new use of supplemental oxygen (or increased oxygen requirement if on chronic oxygen) and requires at the time of randomization low or high flow oxygen devices or use of non-invasive mechanical ventilation (ordinal scale category 5 or 6).
• Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.
• Agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of COVID-19 through Day 29.

You may not qualify if…

• Prior enrollment in ACTT-3 or ACTT-4. Note: this includes subjects whose participation in ACTT was terminated early.
• On invasive mechanical ventilation at the time of randomization (ordinal scale category 7).
• Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours of randomization.
• Positive test for influenza virus during the current illness (influenza testing is not required by protocol).
• Subjects with a low glomerular filtration rate (eGFR), specifically:
• Subjects with an eGFR 15-30 mL/min are excluded unless in the opinion of the PI, the potential benefit of participation outweighs the potential risk of study participation.
• All subjects with an eGFR <15 mL/min
• All subjects on hemodialysis and/or hemofiltration at screening, irrespective of eGFR are excluded.
• Neutropenia (absolute neutrophil count <700 cells/microliter, 0.7 x 10\^3/microliter).
• Lymphopenia (absolute lymphocyte count <200 cells/microliter, 0.20 x 10\^3/microliter).
• Received five or more doses of remdesivir including the loading dose, outside of the study as treatment for COVID-19.
• Pregnancy or breast feeding (lactating women who agree to discard breast milk from Day 1 until two weeks after the last study product is given are not excluded).
• Allergy to any study medication.
• Received convalescent plasma or intravenous immunoglobulin [IVIg] for COVID-19, the current illness for which they are being enrolled.
• Received any of the following in the two weeks prior to screening as treatment of COVID-19:
• More than one dose of baricitinib for the treatment of COVID-19;
• Other small molecule tyrosine kinase inhibitors (e.g. imatinib, gefitinib, acalabrutinib, etc.);
• monoclonal antibodies targeting cytokines (e.g., TNF inhibitors, anti-interleukin-1 [IL-1], anti-IL-6 [tocilizumab or sarilumab], etc.);
• monoclonal antibodies targeting T-cells or B-cells as treatment for COVID-19. Note: receipt of anti-SARS-CoV-2 monoclonal antibody (mAb) prior to enrollment (e.g. bamlanivimab) for their current COVID-19 illness is not exclusionary
• Use of probenecid that cannot be discontinued at study enrollment.
• Received 6 mg or more of dexamethasone by mouth (po) or Intravenous (IV) (or equivalent for other glucocorticoids) in one day, on more than one day, in the 7 days prior to time of randomization. Note: 6 mg dexamethasone dose equivalents include 40 mg prednisone, 32 mg methylprednisolone and 160 mg hydrocortisone.
• Received > / = 20 mg/day of prednisone po or IV (or equivalent for other glucocorticoids) for > / = 14 consecutive days in the 4 weeks prior to screening.
• Have diagnosis of current active or latent tuberculosis (TB), if known, treated for less than 4 weeks with appropriate therapy (by history only, no screening required).
• Serious infection (besides COVID-19), immunosuppressive state, or immunosuppressive medications that in the opinion of the investigator could constitute a risk when taking baricitinib or dexamethasone.
• Have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. Note: Use of non-live (inactivated) vaccinations including SARS-CoV-2 vaccine is allowed for all subjects.

Where it is running

• UCSF Fresno Center for Medical Education and Research - Clinical Research Center — Fresno, California, United States
• University of California San Diego Health - Jacobs Medical Center — La Jolla, California, United States
• University of California Los Angeles Medical Center - Westwood Clinic — Los Angeles, California, United States
• University of California Irvine Medical Center - Infectious Disease — Orange, California, United States
• VA Palo Alto Health Care System - Infectious Diseases — Palo Alto, California, United States
• University of California Davis Medical Center - Internal Medicine - Infectious Disease — Sacramento, California, United States
• Kaiser Permanente San Diego Medical Center — San Diego, California, United States
• Naval Medical Center San Diego - Infectious Disease Clinic — San Diego, California, United States
• University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine — San Francisco, California, United States
• Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases — Stanford, California, United States
• Cedars Sinai Medical Center — West Hollywood, California, United States
• VA Eastern Colorado Health Care System — Aurora, Colorado, United States
• Denver Health Division of Hospital Medicine - Main Campus — Denver, Colorado, United States
• Georgetown University Medical Center - Division of Infectious Diseases — Washington D.C., District of Columbia, United States
• University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine — Gainesville, Florida, United States
• University of Florida Health - Jacksonville - Department of Emergency Medicine — Jacksonville, Florida, United States
• University of Miami Miller School of Medicine - Infectious Diseases — Miami, Florida, United States
• Emory Vaccine Center - The Hope Clinic — Decatur, Georgia, United States
• Atlanta VA Medical Center - Infectious Diseases Clinic — Decatur, Georgia, United States
• Tripler Army Medical Center — Honolulu, Hawaii, United States
• Northwestern Hospital - Infectious Disease — Chicago, Illinois, United States
• University of Illinois at Chicago College of Medicine - Division of Infectious Diseases — Chicago, Illinois, United States
• University of Iowa Hospitals & Clinics - Department of Internal Medicine — Iowa City, Iowa, United States
• Tulane University - Section of Pulmonary Diseases, Critical Care, and Environmental Medicine — New Orleans, Louisiana, United States
• University of Alabama at Birmingham School of Medicine - Infectious Disease — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.